anemia

Biotech

Disc spins faster by paying Mabwell $10M for blood disorder drug

Disc has come a step closer to getting a third blood disorder candidate into the clinic via a licensing deal with Mabwell worth $10 million upfront.
James Waldron Jan 20, 2023 7:21am

Bluebird's sickle cell trial in under-18s back after year hold

Dec 19, 2022 10:55am

Akebia is taking the fight to the FDA months after rejection

Nov 4, 2022 12:02pm

Akebia's anemia drug just misses in a COVID-19 trial

Aug 5, 2022 10:14am

After dispute, Otsuka pays Akebia $55M to exit anemia pill pacts

Jul 1, 2022 8:15am

Roivant decants another Vant armed with Eisai blood cancer drug

Feb 14, 2022 8:45am